Endocrine Therapy for DCIS After Surgery and Radiation

Primary Recommendation: Aromatase Inhibitor

The National Comprehensive Cancer Network recommends anastrozole 1 mg orally once daily for 5 years as the preferred endocrine therapy option for postmenopausal women with ER-positive DCIS after surgery and radiation, with a Category 1 recommendation for patients treated with breast-conserving therapy followed by radiation 1, 2, 3, 4, 5
Anastrozole provides a particular advantage in women under 60 years of age and those with thromboembolic concerns, with a statistically significant improvement in breast cancer-free interval compared to tamoxifen (HR 0.73, 95% CI 0.56-0.96, p=0.0234) 1
The 10-year breast cancer-free interval for anastrozole is 93.1% compared to 89.1% for tamoxifen, with the benefit most pronounced in younger postmenopausal women (under 60 years) 1

Tamoxifen 20 mg daily for 5 years remains an appropriate choice, particularly for women with contraindications to aromatase inhibitors (severe osteoporosis, significant bone loss), patient preference based on side-effect profile, or cost or access considerations 1, 2, 3, 4, 5
The National Comprehensive Cancer Network recommends tamoxifen as an alternative option, with a Category 1 recommendation for patients treated with breast-conserving therapy followed by radiation 2, 3, 4

ER-positive DCIS has a strong indication for endocrine therapy, with a Category 1 recommendation for patients treated with breast-conserving therapy followed by radiation 1, 2, 3, 4
ER-negative DCIS has an uncertain benefit and is not recommended for endocrine therapy 2, 3, 4
The risk reduction with anastrozole is limited to ER-positive tumors (HR 0.42, 95% CI 0.25-0.71) 6

Endocrine therapy for DCIS reduces breast cancer incidence but has not demonstrated a survival advantage 6, 2, 3, 4
The benefits of endocrine therapy must be weighed against side effects and quality of life impacts 2, 3, 4

For patients on anastrozole, serial bone mineral density assessments, monitoring for musculoskeletal symptoms, blood pressure monitoring, and lipid panel monitoring are recommended 1, 2, 5
For patients on tamoxifen, baseline and periodic gynecologic evaluation, monitoring for thromboembolic symptoms, and annual eye examinations if visual symptoms develop are recommended 1, 2

Regardless of endocrine therapy choice, history and physical examination every 6-12 months for 5 years, then annually, and annual mammography (first mammogram 6-12 months after completing radiation, Category 2B) are recommended 2, 3, 4